N-[4-(1-{(4-chlorophenyl)[7-chloro-5-(trifluoromethyl)-1H-indazol-3-yl]methyl}butyl)benzoyl]-β-alanine | 1241947-91-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: N-[4-(1-{(4-chlorophenyl)[7-chloro-5-(trifluoromethyl)-1H-indazol-3-yl]methyl}butyl)benzoyl]-β-alanine
• 英文别名: 3-[[4-[1-(4-chlorophenyl)-1-[7-chloro-5-(trifluoromethyl)-2H-indazol-3-yl]pentan-2-yl]benzoyl]amino]propanoic acid
• CAS: 1241947-91-0
• 化学式: C₂₉H₂₆Cl₂F₃N₃O₃
• 分子量: 592.445
• InChiKey: FEBJMXOXKSKMNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.6
• 重原子数：
  40
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  95.1
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE
  申请人：Lin Songnian

  公开号：US20110301082A1

  公开（公告）日：2011-12-08

  Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type (2) diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

  披露了一种胰高血糖素受体拮抗剂化合物。这些化合物可用于治疗2型糖尿病和相关疾病。还包括制药组合物和治疗方法。
• Cell-based production of nonulosonates
  申请人：National Research Council of Canada

  公开号：US10301659B2

  公开（公告）日：2019-05-28

  The present invention relates to the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-β-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-α-D-glucopyranose. Methods for producing the sugars are also provided.

  本发明涉及以细胞为基础生产细菌壬磺酸盐及其生物合成前体。具体地说，本发明提供了生产假酰胺酸、军团酰胺酸、UDP-2,4-二乙酰氨基-2,4,6-三脱氧-β-L-阿托吡喃糖和 UDP-2,4-二乙酰氨基-2,4,6-三脱氧-α-D-吡喃葡萄糖的重组细胞。还提供了生产这些糖的方法。
• Methods For Treating Heart Failure Using Glucagon Receptor Antagonists
  申请人：REMD Biotherapeutics, Inc.

  公开号：US20170143673A1

  公开（公告）日：2017-05-25

  The present invention relates to methods for treating or preventing heart failure using a glucagon receptor antagonist or modulator. In various embodiments, the present invention relates to methods for treating post-myocardial infarction heart failure and lateral ventricular (LV) remodeling. In various embodiments, the present invention relates to methods for treating diabetic cardiomyopathy.
• Cell-Based Production of Nonulosonates
  申请人：National Research Council of Canada

  公开号：US20170145459A1

  公开（公告）日：2017-05-25

  The present invention relates to the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-β-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-α-D-glucopyranose. Methods for producing the sugars are also provided.
• US8318667B2
  申请人：——

  公开号：US8318667B2

  公开（公告）日：2012-11-27